Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
6.78
+0.43 (6.77%)
Dec 26, 2024, 4:00 PM EST - Market closed
Lexeo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
224.19M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 654.00K | -1.00M | -60.53% |
Dec 31, 2021 | 1.66M | 1.14M | 219.59% |
Dec 31, 2020 | 518.48K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLXEO News
- 8 days ago - Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 5 months ago - Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further - Seeking Alpha
- 5 months ago - Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet - Benzinga